Gene Therapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Gene Therapy
Recent findings from Chiba University, Medical Department highlight research in gene therapy
August 14th, 2008
According to a study from Chiba, Japan, "The utility of recombinant Sendai virus (rSeV) has been considerably examined over the last decade as a potent gene transfer candidate in a cytoplasmic gene expression system. Such risks as excessive immune responses associated with this virus administration in vivo however have limited its applicability in clinical settings as is the case with other viral vectors including adenoviruses." "In consequence of extensive assessment on the mechanisms of immune responses against SeV, we found that ex vivo infection of immature dendritic cells (DCs) with SeV demonstrates their spontaneous maturation and activation. We applied this...
Source: Gene Therapy Weekly (2008-08-14)
|
